Sunitinib, a receptor tyrosine kinase inhibitor, has also been shown to inhibit MDSC accumulation, and hence, reduce the immunosuppressive activity of MDSC, in mouse models of colon and lung cancer29 and human renal cell carcinoma patients30. This evidence concerns the gene NTRK1 and hereditary clear cell renal cell carcinoma.